Can erythropoietin improve developmental outcomes for preterm infants?
McPherson
Ronald J
RJ
Department of Pediatrics, University of Washington, Seattle, Washington 98195,USA. neuron@uw.edu
D002657:Child Development / Q000187:drug effects; D002658:Developmental Disabilities / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D064420:Drug-Related Side Effects and Adverse Reactions; D004921:Erythropoietin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D008297:Male; D011994:Recombinant Proteins; D018570:Risk Assessment; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D011994:Recombinant Proteins; D004921:Erythropoietin